Please assess the completion status of the following clinical trial:

Trial Title: Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Able to perform reproducible spirometry according to American Thoracic Society (ATS) criteria~* History of asthma symptoms (e.g., cough, wheezing, shortness of breath) and meets at least one of the following criteria:~  1. Naïve to controller therapy and meeting National Asthma Education and Prevention Program (NAEPP) criteria for mild-moderate persistent asthma (symptoms at least 2 days per week and/or night-time awakenings due to asthma at least 2 nights per month)~ 2. Current uncontrolled asthma (meets NAEPP criteria for mild-moderate persistent asthma) while receiving an ICS dose greater than or equal to 200 ug per day of fluticasone equivalent or some form of non-ICS controller therapy (e.g., montelukast, theophylline, cromolyn)~ 3. Asthma is currently under control while receiving an ICS dose between 300 to 400 ug per day of fluticasone equivalent and willing to consider changing current treatment to monotherapy with one dose of ICS (current standard of care)~ 4. Asthma is currently under control while receiving some form of combination therapy, such as ICS less than or equal to 200 ug per day of fluticasone equivalent in addition to a non-ICS controller therapy (e.g., LABA, montelukast, theophylline, cromolyn), and willing to consider changing current treatment to monotherapy with one dose of ICS (current standard of care)~* FEV1 reversibility of at least 12% following bronchodilator administration (4 puffs) at study visit 1. Individuals will need to hold albuterol, montelukast, theophylline, ipratropium bromide (or other anticholinergics) and LABAs per study instructions prior to reversibility testing. If an individual is receiving these types of medications prior to study visit 1, he/she may be brought back to the clinical center within 1 week following appropriate medication withholding to attempt qualification by reversibility criteria. If the individual does not meet this requirement, they may qualify for enrollment if their PC20 methacholine FEV1 is less than or equal to 12.5 mg/ml at the time of randomization. If FEV1 is less than 70%, thus precluding the methacholine challenge at this visit, then completion of the visit will be postponed several days and an additional attempt to obtain a methacholine challenge test will be made. If the methacholine challenge still cannot be performed, an individual may still qualify by reversibility criteria at this visit.~* History of clinical varicella or varicella vaccine; individuals needing the vaccine may receive it from their primary care physician prior to study entry~* Ability of parent to provide informed consent; verbal assent must be obtained from children less than 7 years of age and written assent must be obtained from children between 7 and 18 years of age~* If female, willing to use an effective form of contraception~Prior to being randomly assigned to a treatment group, participants must meet the following criteria to remain in the study:~* Lack of acceptable asthma control during the 8-week screening period as defined by the following criteria:~  1) On average, on more than 2 days per week, one or all of the following:~ 1. Diary-reported symptoms~ 2. The use of inhaled bronchodilator (not including pre-exercise)~ 3. Peak flows in the yellow zone (less than 80% of post bronchodilator PEF value obtained at study visit 1) OR~* On average, more than 1 night-time awakening due to asthma, during each 2-week period~Exclusion Criteria:~* Corticosteroid treatment for any condition prior to study entry within the following defined timepoints:~  1. Oral - Use within 2 weeks of the screening visit~ 2. Injectable - Use within 2 weeks of the screening visit~ 3. Nasal - May be used at any time during the study at the discretion of the study investigator or primary care physician~* Current or prior use of medications known to significantly interact with corticosteroid disposition (within a 2-week period of study visit 1), including but not limited to carbamazepine, erythromycin or other macrolide antibiotics, phenobarbital, phenytoin, rifampin, or ketoconazole~* Pre-bronchodilator FEV1 less than 60% predicted at study visit 1~* More than three hospitalizations for asthma in the year prior to study entry~* Presence of chronic or active lung disease other than asthma~* Significant medical illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study or would place the participant at increased risk while participating in the study~* History of cataracts, glaucoma, or any other medical disorder associated with an adverse effect to corticosteroids~* Gastroesophageal reflux symptoms not controlled by standard medical therapy~* History of significant asthma exacerbation within 2 weeks of study visit 1 or more than 5 courses of systemic corticosteroids in the year prior to study entry~* History of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure within the 5 years prior to study entry~* History of adverse reactions to ICS, LTRA, or LABA preparations or any of their ingredients~* Receiving hyposensitization therapy other than an established maintenance regimen (i.e., continuous regimen for at least 3 months prior to study entry)~* Pregnant or breastfeeding~* Inability to perform study procedures~* Refusal to consent to a genotype evaluation~* Inability of the child to ingest the study drug~* Cigarette smoking or smokeless tobacco use in the year prior to study entry~* Current participation or participation in the month prior to study entry in another investigational drug trial~* Evidence that the family may be unreliable or nonadherent, or may move from the clinical center area before study completion

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Sequence #1 (Type: EXPERIMENTAL): fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
- Sequence #2 (Type: EXPERIMENTAL): fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
- Sequence #3 (Type: EXPERIMENTAL): fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
- Sequence #4 (Type: EXPERIMENTAL): fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
- Sequence #5 (Type: EXPERIMENTAL): fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
- Sequence #6 (Type: EXPERIMENTAL): fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol

Based on this trial design, predict the completion outcome and termination type (if applicable).